The "Cancer Anorexia - Epidemiology forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This 'Cancer Anorexia - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the cancer anorexia, historical and forecasted epidemiology as well as the cancer anorexia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Cancer Anorexia Epidemiology
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incidence Cases of Anorexia by Cancer Types in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2018 to 2030.
The total incident cases of anorexia by cancer types in the seven major markets was estimated to be 740,055 in 2020.
The total incident cases of anorexia by cancer types in the 7 MM is expected to increase at a CAGR of 1.1% during the forecast period 2021-2030.
In the United States, the incidence population of anorexia by cancer types was 265,539 in 2020.
In 2020, the incident cases of cancer anorexia in advanced cancers, namely, colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer, and liver cancer in the US were 41,812, 140,931, 31,260, 13,416, 16,268 and 21,852, respectively.
In the EU5 countries, the incident population of anorexia by cancer types was maximum in Germany with 72,040 cases, followed by the France with 58,419 cases in 2020. While, Spain accounted for the lowest incident population of the indication with 36,474 cases in 2020.
As per this analysis, Japan had 197,803 incident cases of anorexia by cancer types in 2020.
Country Wise- Cancer Anorexia Epidemiology
The epidemiology segment also provides the Cancer Anorexia epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Scope of the Report
The report covers the descriptive overview of Cancer Anorexia, explaining explaining its causes, signs and symptoms, pathophysiology.
The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan.
The report assesses the disease risk and burden and highlights the unmet needs of Cancer Anorexia.
Ten Year Forecast of Cancer Anorexia
The publisher has analysed incident population of cancer anorexia in the 7MM which suggests that the patient pool will increase during the forecast period of 2021-2030.
Cancer anorexia is one of the most prevalent and troublesome clinical problems experienced by patients with cancer during and after therapy. It is a phenomenon that comes on in patients with cancer, very frequently when they have advanced cancer such as pancreatic and lung cancer and less frequent in patients with cancers of the breast.
There is a data crunch in the EU5 and Japan as not many studies have been conducted in these regions which have mentioned the incidence of cancer anorexia, CC, or CACS. In the US, some studies are available; however, the studies are quoting numbers from previously conducted systematic or review studies, and not many recent studies are available.
From the studies included in the scope of this report, it can be deduced that cancer anorexia is highly incident in cancer patients, especially in highly progressive cancers.
Key Topics Covered:
1 Key Insights
2 Cancer Anorexia Market Overview at a Glance
2.1 Patient Share (%) Distribution of Cancer Anorexia in 2018
2.2 Patient Share (%) Distribution of Cancer Anorexia in 2030
3 Executive Summary of Cancer Anorexia
4 Disease Background and Overview: Cancer Anorexia
4.4 Risk factors and assessment
5 Epidemiology and Patient Population
5.1 Key Findings
5.2 7MM Total Incidence of Anorexia by cancer types
6 Country-wise Epidemiology of Cancer Anorexia
6.1 Assumptions and Rationale
6.2 The United States
6.2.1 Incidence of Anorexia by cancer types in the US
6.3 EU5 Countries
6.3.5 United Kingdom
7 Recognized Establishments
For more information about this report visit https://www.researchandmarkets.com/r/6vn6fa
View source version on businesswire.com: https://www.businesswire.com/news/home/20210415005653/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900